In 2015, our founders pioneered a "moneyball for biotech" approach, pooling promising early-stage research from academia under one financial umbrella to reduce risk and unleash innovation. They recognized that brilliant science was sitting on shelves in universities, waiting for someone to bridge the gap between discovery and patient impact. So they built BridgeBio - a company designed to move at the speed of patient need, not bureaucracy.
Today, BridgeBio has evolved into a global biopharmaceutical leader with our innovative hub-and-spoke model. Teams operate autonomously as focused "spokes," each dedicated to a specific condition or drug candidate, while our central "hub" provides clinical, regulatory, and commercial expertise. This decentralized structure lets us pursue multiple paths simultaneously, pivot with purpose, and advance first-in-class or best-in-class therapies for genetic diseases and genetically driven cancers. With 3 FDA approvals, 70+ peer-reviewed publications, and 2000+ patients enrolled in clinical trials globally, we're turning beautiful science into meaningful medicines - from LGMD2I/R9 and ATTRv amyloidosis to achondroplasia and beyond. At BridgeBio, we don't just hope for change. We drive it.
